Complimentary Passes Available for a Limited Time
In-Person Only | Must be Government, Academia, Pharma, Biotech, or Regulatory to Qualify | $99 After April 10
EXHIBIT HALL & KEYNOTE PASS
TUESDAY, MAY 19 | 4:30 – 6:00 pm
PLENARY KEYNOTE PRESENTATION: AI Runs on Power: The Physical Limits Shaping the Future of Life Sciences
WEDNESDAY, MAY 20 | 8:00 – 9:30 am
PLENARY KEYNOTE PRESENTATION: The Collaboration Breakthrough: How Federated Learning Is Rewriting the Rules of Drug Discovery
Mohammed AlQuraishi, PhD, Assistant Professor, Systems Biology, Columbia University
Jonathan B. Gilbert, PhD, Senior Director, Ecosystem Growth and Contributor Partnerships, Eli Lilly and Company
José-Tomás Prieto, PhD, Director of AI Programs, Apheris
Woody Sherman, PhD, Founder and Chief Innovation Officer, Psivant Therapeutics
Christina Taylor, PhD, Senior Science Fellow and Computational Molecular Design Lead, Bayer
EXHIBIT HALL & KEYNOTE PRESENTATION SCHEDULE:
TUESDAY, MAY 19
6:00 – 7:15 pm Exhibit Hall Open
4:30 – 6:00 pm Plenary Keynote Presentation
6:00 – 7:15 pm Welcome Reception in the Exhibit Hall with Poster Viewing
WEDNESDAY, MAY 20
9:30 am – 5:45 pm Exhibit Hall Open
8:00 – 9:30 am Plenary Keynote Presentation
9:30 – 10:15 am Coffee & Networking in the Exhibit Hall with Poster Viewing
1:35 – 2:25 pm Refreshments & Networking in the Exhibit Hall with Poster Viewing
4:30 – 5:45 pm Best of Show Awards Reception in the Exhibit Hall with Poster Viewing
THURSDAY, MAY 21
8:00 am – 2:30 pm Exhibit Hall Open
8:00 – 8:20 am Innovative Practices Awards
8:20 – 8:35 am Emerging Innovator Award—NEW
8:35 – 9:45 am Plenary Keynote Presentation
9:45 – 10:30 am Coffee Break in the Exhibit Hall with Poster Competition Winners Announced
1:50 – 2:30 pm Refreshment Break in the Exhibit Hall with Poster Viewing
**Exhibit Hours Subject to Change**
The pharmaceutical industry sits on a collective treasure trove of proprietary structural biology data, yet competitive concerns have historically prevented the data sharing necessary to train the most powerful AI models for drug discovery. Federated learning is changing this paradigm, enabling biopharma companies to collaborate on AI model training while keeping sensitive data secure and confidential. This plenary session explores the groundbreaking AI Structural Biology (AISB) Network, where industry leaders are pooling proprietary protein-ligand structure data to collaboratively train OpenFold3, an AI model designed to predict molecular interactions with precision approaching X-ray crystallography. Through the federated computing platform, thousands of experimentally determined protein–small molecule structures remain securely at their original locations while contributing to a shared learning framework that no single organization could achieve alone. This session reveals how federated learning solves the industry's most persistent challenge: unlocking collective intelligence while protecting intellectual property. Attendees will hear directly from consortium leaders about:
- The technical architecture enabling privacy-preserving collaborative AI training across competing organizations
- Real-world implementation of federated learning platforms and computational governance frameworks
- Strategic rationale for industry collaboration: why sharing model training beats going it alone
- Impact and outcomes from early OpenFold3 results in predicting binding affinities and accelerating small molecule discovery
- The future of collaborative AI in biopharma, from structural biology to clinical development
THURSDAY, MAY 21 | 8:00 – 9:45 am
PLENARY KEYNOTE PRESENTATION: Hopscotching Through Drug Discovery: 15 Years of CADD and the Rise of AI
José Duca, PhD, Global Head Computer-Aided Drug Discovery, Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Inc.
Limited Number of Passes Available | In-Person Only | Complimentary Until April 10
(Discount codes not applicable on Exhibit Hall passes)